<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The methylation inhibitor <z:chebi fb="0" ids="50131">5-Aza-2'-deoxycytidine</z:chebi> (5-Aza-CdR, <z:chebi fb="0" ids="50131">decitabine</z:chebi>) has therapeutic efficacy in <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Using microarray analysis, we investigated global changes in gene expression after 5-Aza-CdR treatment in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cell line OCI-AML2, Aza-CdR induced the expression of 81 out of 22 000 genes; 96 genes were downregulated (&gt; or =2-fold change in expression) </plain></SENT>
<SENT sid="3" pm="."><plain>RT-PCR analysis of 10 randomly selected genes confirmed the changes of expression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cells </plain></SENT>
<SENT sid="4" pm="."><plain>Similar results were obtained with primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cells after treatment with 5-Aza-CdR ex vivo and in vivo, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, significantly fewer changes in gene expression and cytotoxicity were detected in <z:mpath ids='MPATH_458'>normal</z:mpath> peripheral blood mononuclear and bone marrow cells or transformed epithelial cells treated with 5-Aza-CdR </plain></SENT>
<SENT sid="6" pm="."><plain>Interestingly, only 50.6% of the induced genes contain putative CpG islands in the 5' region </plain></SENT>
<SENT sid="7" pm="."><plain>To further investigate the significance of promoter methylation in the induced genes, we analyzed the actual methylation status of randomly selected 5-Aza-CdR-inducible genes </plain></SENT>
<SENT sid="8" pm="."><plain>We detected hypermethylation exclusively in the 5' region of the myeloperoxidase (MPO) gene </plain></SENT>
<SENT sid="9" pm="."><plain>DNA methylation inversely correlated with MPO expression in newly diagnosed untreated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients (P&lt; or =0.004) </plain></SENT>
<SENT sid="10" pm="."><plain>In contrast, <z:hpo ids='HP_0000001'>all</z:hpo> other analyzed 5-Aza-CdR-inducible genes revealed no CpG methylation in the promoter region, suggesting a methylation-independent effect of 5-Aza-CdR </plain></SENT>
</text></document>